1. Home
  2. CVM vs CNSY Comparison

CVM vs CNSY Comparison

Compare CVM & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

SELL

Current Price

$1.57

Market Cap

24.1M

Sector

Health Care

ML Signal

SELL

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

HOLD

Current Price

$0.72

Market Cap

20.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVM
CNSY
Founded
1983
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
20.6M
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
CVM
CNSY
Price
$1.57
$0.72
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$12.50
★ $27.75
AVG Volume (30 Days)
101.5K
★ 2.1M
Earning Date
11-27-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 87.61
EPS
★ N/A
N/A
Revenue
$264,033.00
★ $5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$339.01
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 65.45
N/A
52 Week Low
$0.89
$0.43
52 Week High
$7.80
$4.25

Technical Indicators

Market Signals
Indicator
CVM
CNSY
Relative Strength Index (RSI) 53.11 31.96
Support Level $1.01 N/A
Resistance Level $1.80 $2.28
Average True Range (ATR) 0.16 0.42
MACD 0.01 -0.03
Stochastic Oscillator 73.54 7.62

Price Performance

Historical Comparison
CVM
CNSY

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: